Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Pharvaris N.V. (PHVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.55+0.44 (+2.57%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close17.11
Open17.10
Bid7.02 x 2900
Ask28.08 x 1800
Day's Range17.10 - 17.55
52 Week Range13.14 - 22.24
Volume3,781
Avg. Volume15,245
Market Cap581.825M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.46
Earnings DateMay 24, 2022 - May 30, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PHVS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pharvaris N.V.
    Daily – Vickers Top Insider Picks for 05/13/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)

    ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced company-wide support of today’s Hereditary Angioedema International (HAEi) hae day :-) 2022, a global awareness day for hereditary angioedema (HAE). Pharvaris supported the HAE community by partaking in the hae day :-) Activ

  • GlobeNewswire

    Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer

    Pharvaris’ executive team further strengthened by Ms. Schmidt’s deep international experience and biopharmaceutical industry tenure ZUG, Switzerland, May 11, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced the appointment of Joan Schmidt, J.D., to the newly created position of Chief Legal Officer,

  • GlobeNewswire

    Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights

    Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipated in 4Q22Enrollment underway in HAE CHAPTER-1, proof-of-concept Phase 2 prophylactic study using PHVS416 for the prevention of HAE attacks; top-line data anticipated in 4Q22 RAPIDe-2, long-term extension on-demand study of PHVS416 for the treatment of HAE attacks, on-track to initiate in 2H22Continue to execute from a strong financial position with cash and cash eq

Advertisement
Advertisement